Abstract
The past decades of cancer immunotherapy research have provided profound evidence that the immune system is capable of inducing durable tumor regression. Although many commercialized anti-cancer immunotherapies are available to patients, these treatment options only scrape the surface of the potential immune-related treatment possibilities for cancer. Additionally, many individuals are ineligible for established immunotherapies due to their cancer type. The adoptive cell transfer of autologous tumor-infiltrating lymphocytes has been used in humans for over 30 years to treat metastatic melanoma, and continued modifications are making it increasingly more effective against other types of cancer. This comprehensive review outlines this therapy from its infancy through to the present day, bringing to light modifications and optimizations to the traditional workflow, as well as highlighting the influence of new methods and technologies.
| Original language | English |
|---|---|
| Journal | Immuno |
| Volume | 1 |
| Issue number | 3 |
| Pages (from-to) | 194-211 |
| Number of pages | 17 |
| ISSN | 2673-5601 |
| DOIs | |
| Publication status | Published - 9 Jul 2021 |
Keywords
- CRISPR
- T cells
- adoptive cell therapy
- cancer
- cancer immunotherapy
- checkpoint inhibition
- combination therapy
- immunotherapy
- tumor-infiltrating lymphocytes
Fingerprint
Dive into the research topics of 'ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS